Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | CTSA | P10619 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887223 | 1.00 | MTNR1A (0.47) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A | |
| SCHEMBL2882505 | 0.93 | MTNR1A (0.49) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A | |
| SCHEMBL2882501 | 0.93 | MTNR1A (0.49) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A | |
| SCHEMBL2885762 | 0.92 | MTNR1A (0.54) | MTNR1AMTNR1BL3MBTL1FFAR1CTSA | |
| SCHEMBL2884949 | 0.87 | CACNA1A (0.48) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A | |
| SCHEMBL2884954 | 0.87 | CACNA1A (0.48) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A | |
| SCHEMBL2882332 | 0.87 | MTNR1A (0.58) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A | |
| SCHEMBL2882337 | 0.87 | MTNR1A (0.58) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A | |
| SCHEMBL9413687 | 0.86 | CACNA2D1 (0.47) | MEN1KMT2AFFAR1MAPT | |
| SCHEMBL2887330 | 0.83 | PDE4D (0.53) | MTNR1AMTNR1BL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121069-A1 | METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND | MSD K.K. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2042478-A1 | METHOD FOR PRODUCING -DIARYL ELECTRON-WITHDRAWING GROUP SUBSTITUTED COMPOUND | Japan Science and Technology Agency (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121069-A1 | METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND | BMP6, GPR6, ACSL6 | MTNR1A 2869/4885MTNR1B 2349/4885L3MBTL1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.